SynthesisJournal of cutaneous medicine and surgery
Clinical Use and Safety of Self-Tanner (Topical Dihydroxyacetone) in Dermatology: A Systematic Review.
Synthesis in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDihydroxyacetone (DHA) is the key ingredient in commercially available self-tanners, which are a popular alternative to sun-tanning.
objectivesThis systematic review (PROSPERO: CRD42024558929) presents safety and clinical data about topical DHA in human and animal models since its discovery, to guide dermatologists in counseling their patients about DHA, its possible use in cutaneous diseases, and sun protection.
methodsThis systematic review includes 16 studies retrieved in July 2023 from Embase, Medline, Cochrane, and Web of Science, following the preferred reporting items for systematic reviews and meta-analyses guidelines, and from searches of retrieved articles' bibliographies. All studies were critically appraised using Cochrane's Risk of Bias in Non-Randomized Studies of Interventions and the Risk of Bias Tool for Randomized Trials (second version) tools.
resultsMurine model data suggest DHA may provide minimal photoprotection, insufficient to replace sunscreen, and may delay ultraviolet radiation-linked tumor development. Patients with erythropoietic protoporphyria (EPP) and vitiligo may benefit from DHA. No link has been established between DHA and clinically relevant vitamin deficiency and contact dermatitis. Concerns remain about cutaneous free-radical formation and product absorption. DHA's use in psoralen-UVA therapy does not warrant further development. DHA's role in altering the evaluation of melanocytic lesions with dermoscopy is minor.
conclusionsDHA may have some use in patients with vitiligo and EPP. No studies demonstrated harm related to DHA use, though most studies were low-quality, conducted on a few humans or animals, occasionally with product concentrations over the threshold permitted by the European Commission. Unresolved safety concerns about free-radical formation require high-quality research to clarify DHA's long-term health impacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.